Comprehensive strategic R & D infrastructures are one of the EU’s most important tools to identify and address major societal, environmental or economic challenges in the European area. They provide resources, services and equipment that supports and accelerates the entire R & D process. One of the critical R & D infrastructures is the so-called biobanks. Biobanks are one of the most important research infrastructures for biomedical R & D. In order to ensure excellence, interdisciplinarity and applicability of the individual project activities, a comprehensive consortium proposal was prepared to build a common workplace with shared, open access for consortium members and potentially other academic institutions interested in cooperation. We expect that building a system infrastructure will also improve the dynamics of participation in Horizon 2020 projects and other funding schemes at national and international level. Overall objective of the project: expanding and completing research and innovation infrastructure and capacities to develop research and innovation excellence through the development of a biobanking system for cancers and rarity diseases and its integration into an international network of research infrastructures. Since this is a project of strategic importance in the field of biomedicine, academic centres, research centres and parks and health institutions that have biomedical programmes have been integrated into the project and it is assumed that it is in these institutions that the highest quality scientific and research capacities are concentrated with sufficient infrastructure. In all its specific objectives, the project supports the integration, optimisation and further development of research infrastructure, including international scientific and technological cooperation, which is a key element in the implementation of individual project activities. In content, the project is directly linked to domain No.4 RIS3 Population Health and Health Technology, the main trend: Innovative diagnostic and therapeutic procedures and products of personalised/precision medicine. The results and outputs of the project will be fully exploited in the main NACE sector of the domain, Q86 – Health.
